Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Summary

TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα (Signal Regulatory Protein Alpha) and enhances the phagocytosis of cancer cells by macrophages. This is a study to evaluate the safety, tolerability and effectiveness of TQB2928 injection in subjects with advanced malignancies.

Timeline

Start

2022-01-24

Primary completion

2024-01

Completion

2025-01

Drugs

Indications